TrialAllergy2026

Long-Term Efficacy and Safety of Ligelizumab as Re-Treatment in Patients With Chronic Spontaneous Urticaria.

Ana M Gimenez-Arnau et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.